A COMPARATIVE STUDY ON THE SAFETY AND EFFICACY OF TOPICAL BIMATOPROST WITH TIMOLOL MALEATE IN GLAUCOMA PATIENTS

被引:0
|
作者
Polagani, Padma [1 ]
Maddikunta, Sridhar Venkat [2 ]
Balakrishna, Namala [2 ]
Kondaveti, Souris [2 ]
机构
[1] Kakatiya Med Coll, Dept Pharmacol, Warangal, Telangana, India
[2] Osmania Med Coll & Hosp, Dept Pharmacol, Hyderabad, Telangana, India
来源
JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS | 2016年 / 5卷 / 46期
关键词
IOP; PACG; POAG; Bimatoprost; Timolol Maleate;
D O I
10.14260/jemds/2016/670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Glaucoma is a group of disorders characterized by increase in Intraocular Pressure OOP), which can damage the optic nerve and if untreated can lead to gradual peripheral vision loss and irreversible blindness. Glaucoma classified into primary and secondary glaucoma. Primary glaucoma has two types Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Glaucoma is the second leading cause of blindness. Worldwide, it is estimated that about 66.8 million people have visual impairment from glaucoma with 6.8 million suffering from blindness. AIMS AND OBJECTIVE To assess the level of IOP reduction of bimatoprost with timolol maleate and its statistical analysis. To compare the IOP lowering efficacy of bimatoprost with timolol maleate. To study the adverse drug reaction profiles of both the drugs. MATERIALS AND METHODS This study was designed to compare the efficacy and safety of topical anti-glaucoma drugs, Bimatoprost (0.03%) and Timolol maleate (0.5%) in patients with POAG attending at Regional Eye Hospital, Warangal. RESULTS In this study mean reduction of IOP at 2 wks., 6 wks., 12 wks., 24 wks. were 6.60 mmHg (23.21%), 9.6 mmHg (33.76%), 10.00 mmHg (38.68%), 11.20 mmHg (39.39%) for Bimatoprost and 4.20 mmHg (15.07%), 6.24% mmHg (23.39%), 7.36 mmHg (25.91%) and 7.64 mmHg (26.56%) for Timolol group respectively. STATISTICAL METHOD Student's 't' test was used for analysis of results. CONCLUSION Bimatoprost 0.03% ophthalmic solution was highly efficacious, well tolerated, systemically safe and minimal ocular side effects and less drug withdraw. It can be used as first line therapy to treat cases of POAG to reduce IOP. The only limitation for its use is regarding its cost. The topical bimatoprost preparations are expensive when compared to the topical Timolol maleate. But considering the reduction in IOP, the modifiable factor for preventing the progression of optic nerve head damage and preservation of visual function hence increase the quality of vision and life.
引用
收藏
页码:2974 / 2979
页数:6
相关论文
共 50 条
  • [41] Synergistic Effect of Once Daily Topical 0.03% Bimatoprost and 0.5% Timolol Maleate on Intraocular Pressure Reduction in Normal Beagles
    Telford, Corbin
    Gilger, Brian C.
    Salmon, Jacklyn H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [42] In vitro In-vivo Investigation of Topical W/O Microemulsion of Timolol Maleate for Treatment of Glaucoma
    Hegde, Rahul R.
    Bhattacharya, Shiv S.
    Verma, Anurag
    Ghosh, Amitava
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (10): : 1467 - 1475
  • [43] Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma
    Netland, PA
    Weiss, HS
    Stewart, WC
    Cohen, JS
    Nussbaum, LL
    Abrams, D
    Schwartz, G
    Hughes, P
    Adelson, A
    Brink, M
    Myers, M
    Bahr, R
    Dowling, JL
    Richards, F
    Geltzer, A
    Hofmann, RJ
    SnadyMcCoy, L
    Bartnik, LA
    Beneke, J
    Barr, L
    Muroski, D
    Neal, J
    Clevenger, C
    Summitt, B
    Lee, A
    Cohen, J
    Riccio, KA
    Luechauer, A
    DuBiner, H
    Cribbs, S
    Laibovitz, R
    Neck, K
    Mundorf, T
    Otero, D
    Netland, PA
    Vivolo, DA
    Schwartz, L
    Carmichael, P
    Conner, R
    Nowinski, T
    Kesselring, J
    Bollenbach, A
    Foley, A
    Stewart, W
    Stewart, J
    Weiss, H
    Schwartz, A
    Latham, BD
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 123 (04) : 465 - 477
  • [44] Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma
    Hommer, Anton
    Hubatsch, Douglas A.
    Cano-Parra, Juan
    JOURNAL OF OPHTHALMOLOGY, 2015, 2015
  • [45] Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma
    Öztürk, F
    Ermis, SS
    Inan, UU
    Asagidag, A
    Yaman, S
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 21 (01) : 68 - 74
  • [46] Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies
    Hamacher, T
    Schinzel, M
    Schölzel-Klatt, A
    Neff, HM
    Maier, H
    Schlaffer, G
    Beausencourt, E
    Jütte, M
    Scholz, R
    Lorger, C
    Stewart, WC
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (10) : 1295 - 1298
  • [47] Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
    Bell, Nicholas P.
    Ramos, Jose L.
    Feldman, Robert M.
    CLINICAL OPHTHALMOLOGY, 2010, 4 : 1331 - 1346
  • [48] Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients
    Martinez, A.
    Sanchez, M.
    EYE, 2009, 23 (04) : 810 - 818
  • [49] Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients
    A Martinez
    M Sanchez
    Eye, 2009, 23 : 810 - 818
  • [50] Orbital fat atrophy in glaucoma patients treated with topical bimatoprost can bimatoprost cause enophthalmos?
    Tappeiner, C.
    Perren, B.
    Iliev, M. E.
    Frueh, B. E.
    Goldblum, D.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2008, 225 (05) : 443 - 445